Best Stocks To Buy For 2017


International Lithium [TSXV:ILC] (OTCPK:ILHMF) – Price = CAD 0.13

International Lithium (ILC) is a small lithium explorer/project generator with four joint venture lithium projects, and one fully-owned lithium project:

Mariana lithium brine in Argentina (20% ILC: 80% GFL). ILC can increase to 30% via a 10% back-in right. Jiangxi Ganfeng Lithium (GFL) is committed to US$10m in expenditures at Mariana. This is their flagship project. Avalonia lithium pegmatite in Ireland (45% ILC: 55% GFL). GFL has the option to acquire an additional 24% after spending US$10m, or producing a Feasibility Study [FS]. Mavis Lake and Raleigh lithium pegmatite in Ontario Canada (49% ILC: 51% Pioneer Resources Limited (OTC:PIONF)). 100% of the Forgan Lake pegmatite project in Canada.


Note that Avalon, Mavis Lake, Raleigh, and Forgan Lake also have rare earths. Jiangxi Ganfeng Lithium (SHE:002460) has an 18.1% stake in ILC in addition to the above joint venture partnerships.

The company states: “International Lithium Corp.’s mission is to find, explore and develop projects that have the potential to become world-class lithium, potash and rare metal deposits.” Their business model involves taking on partners that then help pay the majority of the expenses in getting the project to an advanced stage, thereby minimizing investor dilution, and financing risk.

Best Stocks To Buy For 2017: Tata Motors Ltd(TTM)


Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    I’ve been watching Tata Motors Ltd. (TTM) over the past few years with increasing interest. As India’s largest carmaker, it stands to benefit from the tenfold projected growth in the middle class in both India and China over the next decade.

Best Stocks To Buy For 2017: Live Nation Entertainment, Inc.(LYV)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    For his “Executive Decision” segment, Cramer checked in with Michael Rapino, president and CEO of Live Nation Entertainment (LYV) , a stock that’s up 44% since Cramer last spoke with him a little more than a year ago but also one that fell 3% in today’s session on what appeared to be solid quarterly results.

Best Stocks To Buy For 2017: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By JACK HOUGH]

    Celgene’s main risk is a little like AMC’s zombies. It will generate more than 60% of its revenue this year from a single medicine called Revlimid, used primarily to treat a type of cancer called multiple myeloma. But Revlimid is gaining regulatory approval for an expanding number of uses. It has plenty of growth potential overseas, and shows promise in combination therapies. And it has more than a decade of remaining patent protection. Analysts predict double-digit yearly revenue growth for Revlimid through the end of the decade.

    By then, Celgene is expected to have four drugs with yearly sales in the billions of dollars, versus just Revlimid today. And a robust pipeline of medicines in development provides ample opportunity for new successes. Management has set a goal of $21 billion in yearly revenue by 2020, up from a projected $9.2 billion this year. If it’s successful, two things are likely to happen. First, Revlimid’s contribution is likely to drop below half of revenue by then. Second, earnings per share could more than double, as Celgene’s growing size offers better leverage on its research and marketing expenses. Shares sell for 22 times this year’s earnings consensus—inexpensive considering the growth outlook.  

  • [By Peter Graham]

    A long term performance shows shares of small cap cancer stocks Juno Therapeutics and Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) underperforming whileKite Pharma Inc (NASDAQ: KITE)andlarge cap Celgene Corporation (NASDAQ: CELG) have performed better:

  • [By Todd Campbell]

    The company is also going to continue early stage research into its CAR-T program, including its work on bb2121, a BCMA-targeting therapy that’s being developed with Celgene (NASDAQ:CELG) for multiple myeloma.

  • [By WWW.THESTREET.COM]

    Sometimes you just want to keep a list of stocks that act too well. At the top of the list? Celgene (CELG) . This company had a very good quarter with lots of growth but has been stuck in a range forever. Now it is back to its old self, unlike the other major biotechs, and it’s been soaring. Just plain bothersome not to know.

  • [By Chris Lange]

    Celgene Corp. (NASDAQ: CELG) short interest for this settlement date increased to 9.97 million shares from the previous 9.26 million. Shares closed most recently at $121.06, in a 52-week range of $93.05 to $127.00.

  • [By WWW.THESTREET.COM]

    Originally published Nov. 17 at 3:41 p.m. EDT

    The consideration of the contrary has been a theme all week. And here in ” Don’t Run With the Crowd: Embrace the Contrary.”   Miami madness (of a real estate kind)   Mark Grant is scared by our currency’s strength.   Danielle on scenarios.   Boockvar to subscriber Bad Golfer!   JC Penney ( JCP) short puts–a 100% win. (Shorting options frequently ends differently!)   Just say no to closed-end muni-bond funds.   DRYS is all wet.   Could iPhone manufacturing be coming back home?   On inflation breakevens–a picture that speaks volumes.   The market moved higher from the “get go”–in large measure it seems to be a response to the better economic data this morning.   At 3 p.m. stocks were near the day’s highs.   I shorted The Cisco Kid last night. Sticking with this short rental. I added to my ProShares UltraShort S&P500 ETF ( SDS) long (growing ever larger). My net short exposure–is now between small and medium-sized at the close. The US. dollar, as discussed above, continued to rip higher against the euro. I am concerned. Mark Grant is concerned. The market is not concerned. The price of crude oil (down $0.20) settled lower after yesterday’s robust gains. Gold fell $9 as it continues to break down–closing in on $1,200. Ag commodities: wheat up $0.07, corn up $0.04, soybeans up $0.05 and oats up $0.02. Lumber up $7 following the big housing number this morning. Bonds schmeissed . .. iShares Barclays 2

Best Stocks To Buy For 2017: Texas Instruments Incorporated(TXN)


Advisors’ Opinion:

  • [By Laurie Kulikowski]

    We rate TEXAS INSTRUMENTS INC as a Buy with a ratings score of A+. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, good cash flow from operations, solid stock price performance and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. 

  • [By WWW.THESTREET.COM]

    Chips from Texas Instruments (TXN) are built into a lot of devices that matter, Cramer said, and if investors want autonomous vehicles, they should be looking at Analog Devices (ADI) .

  • [By Jon C. Ogg]

    Texas Instruments Inc. (NASDAQ: TXN) closed out 2016 at $72.97, and Merrill Lynch has a price objective of $82.00. If you consider the 2.7% dividend yield, Merrill Lynch is calling for Texas Instruments to generate a return of 15%. What investors might want to consider is that the consensus analyst target price is $74.89, very close to the current price, but Merrill Lynch’s price objective is exactly $10 less than the most aggressive price target on Wall Street. Texas Instruments has a 52-week range of $46.73 to $75.25. RBC was also positive here on Texas Instruments and other large caps.